Brief: Eiger Biopharmaceuticals Says Debtors Will Continue To Operate Their Businesses As "Debtors-In-Possession" Under Jurisdiction Of Bankruptcy Court
01/04/2024 21:57
April 1 (Reuters) - Eiger BioPharmaceuticals Inc
EIGR.O :
* EIGER BIOPHARMACEUTICALS INC: DEBTORS WILL CONTINUE TO
OPERATE
THEIR BUSINESSES AS "DEBTORS-IN-POSSESSION" UNDER JURISDICTION
OF BANKRUPTCY COURT
Source text for Eikon: ID:n0001193125-24-083403
Further company coverage: EIGR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Eiger Biopharmaceuticals
See all newsBrief: Eiger Biopharmaceuticals On Sept 5, Bankruptcy Court Entered Order Confirming Fifth Amended Joint Plan Of Liquidation Of Co & Its Debtor Affiliates
Amylyx to buy bankrupt Eiger's experimental drug to treat low blood sugar
Brief: Eiger Biopharmaceuticals And Amylyx Entered Into An Asset Purchase Agreement
Eiger BioPharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary
Eiger BioPharmaceuticals Inc expected to post a loss of $7.50 a share - Earnings Preview